Wall Street analysts predict that DENTSPLY SIRONA Inc (NASDAQ:XRAY) will announce earnings per share of $0.59 for the current fiscal quarter, according to Zacks. Nine analysts have provided estimates for DENTSPLY SIRONA’s earnings. The highest EPS estimate is $0.62 and the lowest is $0.55. DENTSPLY SIRONA posted earnings per share of $0.65 in the same quarter last year, which indicates a negative year over year growth rate of 9.2%. The firm is expected to report its next earnings results on Wednesday, August 8th.
On average, analysts expect that DENTSPLY SIRONA will report full year earnings of $2.57 per share for the current financial year, with EPS estimates ranging from $2.52 to $2.61. For the next fiscal year, analysts expect that the firm will post earnings of $2.84 per share, with EPS estimates ranging from $2.72 to $3.10. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that follow DENTSPLY SIRONA.
Get DENTSPLY SIRONA alerts:
DENTSPLY SIRONA (NASDAQ:XRAY) last announced its quarterly earnings data on Sunday, May 6th. The medical instruments supplier reported $0.45 EPS for the quarter, topping the Zacks’ consensus estimate of $0.42 by $0.03. DENTSPLY SIRONA had a positive return on equity of 8.63% and a negative net margin of 38.32%. The company had revenue of $956.10 million during the quarter, compared to the consensus estimate of $942.20 million. During the same quarter last year, the company earned $0.49 EPS. The company’s quarterly revenue was up 6.2% on a year-over-year basis.
XRAY has been the subject of a number of research reports. ValuEngine downgraded DENTSPLY SIRONA from a “sell” rating to a “strong sell” rating in a research report on Tuesday, May 8th. HC Wainwright set a $63.00 target price on DENTSPLY SIRONA and gave the stock a “hold” rating in a research report on Tuesday, March 27th. Credit Suisse Group cut their target price on DENTSPLY SIRONA from $73.00 to $69.00 and set an “outperform” rating for the company in a research report on Friday, March 2nd. Morgan Stanley cut their target price on DENTSPLY SIRONA from $65.00 to $54.00 and set an “overweight” rating for the company in a research report on Thursday, June 14th. Finally, Barclays restated a “hold” rating and set a $55.00 target price on shares of DENTSPLY SIRONA in a research report on Tuesday, May 8th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and nine have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $62.23.
Shares of XRAY stock traded up $0.38 during mid-day trading on Friday, reaching $44.95. The stock had a trading volume of 2,287,279 shares, compared to its average volume of 2,538,671. The company has a current ratio of 2.23, a quick ratio of 1.46 and a debt-to-equity ratio of 0.25. DENTSPLY SIRONA has a one year low of $41.64 and a one year high of $68.98. The company has a market capitalization of $10.26 billion, a P/E ratio of 16.90, a P/E/G ratio of 2.34 and a beta of 1.23.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 13th. Shareholders of record on Friday, June 29th will be given a $0.0875 dividend. The ex-dividend date is Thursday, June 28th. This represents a $0.35 annualized dividend and a yield of 0.78%. DENTSPLY SIRONA’s payout ratio is 13.16%.
In other DENTSPLY SIRONA news, CEO Donald M. Jr. Casey acquired 22,500 shares of the business’s stock in a transaction on Wednesday, May 9th. The stock was purchased at an average price of $44.52 per share, for a total transaction of $1,001,700.00. Following the transaction, the chief executive officer now owns 92,408 shares in the company, valued at approximately $4,114,004.16. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Nicholas W. Alexos acquired 50,000 shares of the business’s stock in a transaction on Wednesday, May 9th. The stock was acquired at an average price of $44.71 per share, with a total value of $2,235,500.00. Following the transaction, the chief financial officer now owns 25,411 shares in the company, valued at approximately $1,136,125.81. The disclosure for this purchase can be found here. In the last quarter, insiders sold 7,856 shares of company stock valued at $349,153. Corporate insiders own 1.93% of the company’s stock.
A number of institutional investors and hedge funds have recently modified their holdings of the business. BlackRock Inc. raised its position in DENTSPLY SIRONA by 0.7% in the 1st quarter. BlackRock Inc. now owns 14,269,268 shares of the medical instruments supplier’s stock valued at $717,889,000 after purchasing an additional 99,455 shares during the last quarter. Generation Investment Management LLP raised its position in DENTSPLY SIRONA by 115.6% in the 4th quarter. Generation Investment Management LLP now owns 9,011,670 shares of the medical instruments supplier’s stock valued at $593,238,000 after purchasing an additional 4,831,112 shares during the last quarter. Veritas Asset Management LLP increased its stake in shares of DENTSPLY SIRONA by 37.2% in the 1st quarter. Veritas Asset Management LLP now owns 8,417,655 shares of the medical instruments supplier’s stock valued at $423,492,000 after buying an additional 2,281,200 shares during the period. Clearbridge Investments LLC increased its stake in shares of DENTSPLY SIRONA by 5.1% in the 4th quarter. Clearbridge Investments LLC now owns 6,958,367 shares of the medical instruments supplier’s stock valued at $458,069,000 after buying an additional 340,634 shares during the period. Finally, Jackson Square Partners LLC increased its stake in shares of DENTSPLY SIRONA by 8.8% in the 4th quarter. Jackson Square Partners LLC now owns 6,891,530 shares of the medical instruments supplier’s stock valued at $453,669,000 after buying an additional 556,624 shares during the period. Hedge funds and other institutional investors own 93.80% of the company’s stock.
About DENTSPLY SIRONA
DENTSPLY SIRONA Inc designs, develops, manufactures, and markets various dental and oral health products, and other consumable healthcare products primarily for the professional dental market worldwide. The company operates in two segments, Technologies & Equipment; and Consumables. Its dental supplies include endodontic instruments and materials, dental anesthetics, prophylaxis pastes, dental sealants, impression materials, restorative materials, tooth whiteners, and topical fluoride products; and small equipment products comprise dental hand pieces, intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers.
Get a free copy of the Zacks research report on DENTSPLY SIRONA (XRAY)
For more information about research offerings from Zacks Investment Research, visit Zacks.com